From 12th to 14th May 2025, Aceso Therapeutics participated in Bio€quity Europe 2025 in Bruges, Belgium, to showcase our innovative bitherapy for cystic fibrosis — a dual therapy with a unique mechanism to restore CFTR activity. The event was well organised, with an excellent program, and attracted high-quality participants, enabling us to connect with promising investors and partners.
Our goal is to secure funding for preclinical regulatory studies in order to support our planned Investigational New Drug (IND) submission in 2028. This event opened up valuable opportunities for future collaborations to advance our project.
We left Bruges feeling energised and motivated, with new opportunities to further our mission of improving the lives of patients with cystic fibrosis.
